Cardiovascular and digestive diseases frequently share the same risk factors such as obesity, unhealthy diet, or several social behaviors, and the increasing prevalence of patients with overlapped cardiovascular and digestive symptoms is a challenging problem in the daily practice. Patients with gastro-esophageal reflux disease can exhibit various forms of chest pain that can be very similar to angina. Furthermore, antithrombotic therapies used for preventive or curative purposes in patients with cardiovascular diseases are frequently associated with gastrointestinal side effects including bleeding. At the same time, in patients with coronary stents presenting to the emergency department with chest pain, angina triggered by stent thrombosis or restenosis should be differentiated from angina-like symptoms caused by a gastrointestinal disease. The aim of this review was to present the complex inter-relation between gastroesophageal diseases and angina in patients on dual antiplatelet therapy following an acute coronary syndrome, with a particular emphasis on the role of anemia resulting from occult or manifest gastrointestinal bleeding, as a precipitating factor for triggering or aggravating angina.
extensively studied in order to reduce the mortality risk associated to chest pain with unknown etiology. [5] [6] [7] In patients with acute chest pain, initiation of an adequate diagnostic strategy is essential for elucidating the etiology of chest pain. Due to the devastating consequences of misdiagnosing an acute coronary syndrome (ACS), the first diagnostic approach should be oriented towards the confirmation or exclusion of a significant coronary artery disease (CAD) as the source of the chest pain. In the eventuality that CAD has been ruled out, the next step of evaluation is frequently represented by upper digestive endoscopy for diagnosing a possible gastrointestinal disease as the source of the pain. Such gastrointestinal etiology of angina-like symptoms could be represented by GERD, gastritis, or gastro-duodenal ulcer. 5 However, due
to the low prevalence of mucosal findings in patients with GERD, endoscopy is nowadays considered of limited value in patients with non-cardiac chest pain. 6, 7 In many cases with endoscopy-negative non-cardiac chest pain, the etiology of the angina-like symptoms can be functional or psychiatric.
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It has also been shown that patients with severe GERDrelated symptoms had an increased risk of developing atrial fibrillation (AF), and treatment with proton pump inhibitors may facilitate conversion to sinus rhythm.
However, the current studies did not succeed to demonstrate the casual relationship between GERD and AF. 8 The use of dual antiplatelet therapy (DAPT), consisting in clopidogrel plus low-dose aspirin, significantly reduced cardiovascular mortality in patients suffering an acute myocardial infarction (AMI) and in those undergoing a percutaneous coronary intervention (PCI), however with the cost of increasing the rate of gastrointestinal (GI) events, including bleeding. 3, 9, 10 Therefore, the management of patients with cardiovascular diseases who are on DAPT and present recurrent chest pain mimicking angina can be challenging in many clinical settings.
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The aim of this review was to present the complex inter-relation between gastroesophageal diseases and chest pain in patients on dual antiplatelet therapy following an acute coronary syndrome, with a particular emphasis on the role of anemia resulting from occult or manifest gastrointestinal bleeding, as a precipitating factor for triggering or aggravating angina. to 75 mg clopidogrel therapy in patients with stable coronary artery disease. 28 In an observational study on a general population of 2.9 million subjects, a 1. Currently, the data obtained from randomized controlled trials is lacking convincing clinical evidence to support the negative effect of PPIs in patients with indication for DAPT. bosis, and this therapy should be maintained for a long term. 15, 42 The optimal duration of DAPT should be assessed based on validated risk scores such as the PRECISE-DAPT (at the moment of stent implantation) or DAPT score (after one year of uneventful DAPT), which evaluate the ischemic and bleeding risk of patients with stent implantation and offer guidance for DAPT duration.
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ETIOLOGY Of ACuTE CHEST PAIN IN PATIENTS wITH CORONARY STENTS
Acute chest pain is one of the most frequent complain of patients presenting at the emergency department, and approximately 20-25% of these patients are diagnosed with an ACS. 45 In patients with coronary stents presenting to the emergency department with chest pain, angina triggered by stent thrombosis or restenosis should be differentiated from angina-like symptoms caused by a gastrointestinal disease.
Other frequent etiologies of chest pain include musculoskeletal, pulmonary, gastrointestinal, and psychiatric diseases. 46 In emergency settings, it is paramount to rule out the major life-threatening conditions that may represent the underlying cause for acute chest pain. These pathologies include acute myocardial infarction, aortic dissection, pulmonary artery embolism, tension pneumothorax, and Boerhaave syndrome. 47 
ANEmIA fOLLOwING GASTROINTESTINAL BLEEDING -A PRECIPITATING fACTOR fOR POST-STENTING ANGINA
In patients with implanted stents, a significant precipitating factor for developing recurrent ischemic events is represented by anemia that can result from occult or manifest gastrointestinal bleeding. Figure 1 summarizes the approach of patients with implanted coronary stents presenting with chest pain and the role of anemia as precipitating factor for developing angina.
A recent study conducted by Giustino et al. in patients
on DAPT for an implanted DES revealed that compared to patients with normal hemoglobin levels, those with anemia presented significantly higher rates of major adverse cardiovascular events (9.5% vs. 5.6%, p <0.0001), all-cause mortality (4.0% vs. 1.4%, p <0.0001), as well as major bleeding events (11.8% vs. 7.7%, p <0.0001). 54 Patients on DAPT are at an increased risk of developing both upper and lower gastrointestinal bleeding events, which can subsequently lead to serious anemia in this fragile population. 55, 56 In a recent large cohort study which included 27,707 patients, Gonzalez-Perez et al. concluded that 73% of patients with upper gastrointestinal bleeding and 23% of those with lower gastrointestinal bleeding, being on antiplatelet therapy for a serious coronary event, needed hospitalization. 57 In an observational study which included 122 patients, DAPT was associated with a significant decrease of hemoglobin levels (1.6, 95% CI: 1.2-1.8, p <0.001) and an increased prevalence of anemia after DAPT (9.1% vs. 45.9%).
mANAGEmENT Of GASTROINTESTINAL BLEEDING IN PATIENTS wITH CORONARY STENTS
In case of hemorrhage in a patient on DAPT, with a recently implanted coronary stent, a life-threatening complication could occur if the therapy is interrupted. The standard attitude, after adequate resuscitation, is prompt endoscopic hemostasis within the gastrointestinal tract, and good facilities and specialists should be available to provide this. 58 In case of patients with coronary stents, whenever it is deemed necessary to temporarily discontinue antiplatelet therapy, this should be limited to the P2Y12 inhibitor, but aspirin should be continued.
Even if there is no good-quality prospective study to evaluate the optimal time for cessation of therapy, the P2Y12 inhibitor should be restarted within a maximum of 5 days due to the high risk of stent thrombosis after this time, and to obtain the most suitable balance between hemorrhage and thrombosis risk. 59 A retrospective study in elective or acute settings of PCI reported a frequency of 10.2% of bleeding complication within 1 year after the procedure, with no increase in mortality risk. 60 Dual antithrombotic therapy had a higher risk than single therapy for rebleeding in the lower digestive tract. In a retrospective study (adjusted HR 1.8, p <0.05), 46% of all patients had rebleeding, and the overall mortality rate was 13% within 5 years after hospitalization. 36 There are published data indicating no significant differences in the cardiovascular outcomes and safety be- The majority of published work supports the beneficial effect of adding PPI to a combined antiplatelet therapy for gastro-duodenal lesions, with a more important effect in the population characterized by a high frequency of H. pylori infection. 74 At the same time, the childhood acquisition of H. pylori infection increases the burden of ulcer history, which further increases the risk of bleeding complications at adult age in patients with CAD who require DAPT. This interrelation seems to be related to mucosal scar vulnerability and, probably, to the lack of any effective therapy for H. pylori eradication in patients with previous ulcers.
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CONCLuSIONS
In conclusion, DAPT significantly reduced cardiovascular 
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